Idorsia (IDIA) 주식 개요
바이오 제약 회사인 Idorsia Ltd는 스위스, 미국, 일본, 유럽 및 캐나다에서 미충족 의료 수요를 위한 의약품의 발견, 개발 및 상용화에 종사하고 있습니다. 자세히 보기
IDIA Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharmaceuticals & Biotech opportunity
Idorsia Ltd 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | CHF 3.80 |
| 52주 최고가 | CHF 4.85 |
| 52주 최저가 | CHF 1.25 |
| 베타 | 1.67 |
| 1개월 변동 | 8.17% |
| 3개월 변동 | 5.17% |
| 1년 변동 | 166.99% |
| 3년 변동 | -55.14% |
| 5년 변동 | -83.16% |
| IPO 이후 변동 | -72.15% |
최근 뉴스 및 업데이트
IDIA: Pediatric And Fabry Pipelines Will Support Future Upside Despite Higher Costs
Analysts have reduced their 12 month price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as the main reasons for the change. Analyst Commentary Bullish Takeaways Bullish analysts maintain a positive stance on the shares even after the price target move to CHF 5, which signals that they still see potential upside from current levels.IDIA: Fabry And Pediatric Programs Will Drive Future Upside Despite Higher Costs
Analysts have trimmed their price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as key reasons for the adjustment. Analyst Commentary Recent commentary points to a mixed view on Idorsia, with the reduced price target reflecting both confidence in parts of the story and concern about execution risks and spending.Recent updates
IDIA: Pediatric And Fabry Pipelines Will Support Future Upside Despite Higher Costs
Analysts have reduced their 12 month price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as the main reasons for the change. Analyst Commentary Bullish Takeaways Bullish analysts maintain a positive stance on the shares even after the price target move to CHF 5, which signals that they still see potential upside from current levels.IDIA: Fabry And Pediatric Programs Will Drive Future Upside Despite Higher Costs
Analysts have trimmed their price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as key reasons for the adjustment. Analyst Commentary Recent commentary points to a mixed view on Idorsia, with the reduced price target reflecting both confidence in parts of the story and concern about execution risks and spending.IDIA: Fabry Pipeline Progress Will Continue To Drive Future Upside
Analysts have trimmed their 12 month price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as the key reasons for the reset. Analyst Commentary Bullish Takeaways Bullish analysts are still assigning upside potential to Idorsia shares even after the target reset to CHF 5, which signals that they see value at current levels despite near term headwinds.IDIA: Fabry And Resistant Hypertension Progress Will Continue To Drive Future Upside
Analysts have trimmed their price target on Idorsia to CHF 5 from CHF 6, citing reduced forward visibility and higher operating expenses as key reasons for the adjustment. Analyst Commentary Recent research points to a mixed view on Idorsia, with the reduced price target reflecting both confidence in parts of the story and concern around execution and cost control.IDIA: Fabry And Resistant Hypertension Progress Will Likely Drive Future Upside
Analysts have revised their CHF price targets for Idorsia to reflect updated assumptions for discount rates, revenue growth, profit margins and future P/E. They are now presenting a more balanced view of the company’s risk and earnings potential.IDIA: Fabry And Hypertension Pipeline Advances Will Likely Drive Future Upside
Analysts have adjusted their CHF price target on Idorsia based on updated assumptions around discount rates, revenue, profit margins, and a higher expected future P/E multiple, resulting in a revised valuation framework in CHF terms. What's in the News Idorsia outlined an FDA-agreed Phase 3 registration program for lucerastat in Fabry disease, centered on kidney pathology and including a pivotal biopsy study plus a second trial comparing oral therapy with current standard-of-care to support a potential market authorization pathway (Key Developments).IDIA: Hypertension And Insomnia Pipeline Progress Will Likely Drive Future Upside
Analysts have trimmed their price target on Idorsia to reflect a slightly lower profit margin outlook and a higher assumed future P/E of 31.60x, while keeping their fair value estimate broadly unchanged. What's in the News Idorsia signed an exclusive license and supply agreement with EMS S.A. to bring QUVIVIQ (daridorexant) to patients across Latin America.IDIA: Hypertension And Insomnia Franchise Will Likely Drive Future Upside
Analysts have adjusted their price target on Idorsia slightly lower to reflect updated assumptions around fair value, a modestly higher discount rate, more conservative revenue growth expectations, a similar profit margin outlook, and a higher future P/E multiple. What's in the News Publication of Phase 3 MODIFY and open label extension data for lucerastat in Fabry disease, with results in Nature Communications highlighting sustained biomarker reductions and signals on renal and cardiac function in a small patient population.IDIA: Hypertension And Insomnia Assets Will Likely Drive Future Upside
Analysts have kept their price target for Idorsia broadly unchanged. They cite only small tweaks to inputs such as a slightly higher discount rate, steady revenue growth and profit margin assumptions, and a marginally adjusted future P/E multiple as the basis for their updated view.Idorsia Ltd (VTX:IDIA) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Dec 22
IDIA: Hypertension And Insomnia Portfolio Will Likely Deliver Upside From Current Levels
Analysts have raised their price target for Idorsia significantly, citing a higher fair value estimate of 5.0 dollars, stronger anticipated revenue growth, and an expectation of a materially higher future price to earnings multiple, partially offset by a slightly lower discount rate. What's in the News Idorsia reaffirmed 2025 guidance, targeting around CHF 130 million in QUVIVIQ net sales and a US-GAAP operating loss of about CHF 55 million for the global business, supported by approximately CHF 165 million EBIT from partnered activities (corporate guidance).IDIA: Hypertension And Insomnia Portfolio Will Likely Fail To Justify Current Price
Analysts have modestly raised their price target on Idorsia, citing a slightly lower perceived risk profile and a marginally stronger long term profit outlook that supports a small increase in fair value, now estimated at approximately 2.00. What's in the News Reaffirmed 2025 guidance, projecting QUVIVIQ net sales around CHF 130 million, partnered business US-GAAP EBIT of about CHF 165 million, and a global US-GAAP operating loss of roughly CHF 55 million, mainly driven by the amended Viatris deal (corporate guidance).IDIA: Limited Near-Term Upside Expected Despite Recent Price Reassessment
Narrative Update on Idorsia Analysts have raised their price target for Idorsia, doubling it from CHF 1 to CHF 2. This change is attributed to improved outlooks in key financial metrics, including a slightly lower discount rate and stable revenue growth projections.Little Excitement Around Idorsia Ltd's (VTX:IDIA) Revenues As Shares Take 29% Pounding
Nov 07IDIA: Near-Term Risks Will Likely Limit Upside Despite Price Target Lift
Analysts have increased their price target for Idorsia by CHF 1.00 to CHF 2.00. They cite improved revenue growth projections and a more favorable future price-to-earnings outlook, despite a slightly higher discount rate and modestly lower profit margin expectations.Global Expansion And FDA Review Will Moderate Overvaluation
Despite a decline in revenue growth forecasts, the significant rise in Idorsia’s future P/E multiple underpins the sharp increase in its consensus analyst price target from CHF2.00 to CHF4.00. What's in the News Simcere Pharmaceuticals launched QUVIVIQ (daridorexant), Idorsia's dual orexin receptor antagonist for insomnia, in China, with approval highlighting its differentiated clinical profile and lack of psychotropic labeling.Idorsia Ltd (VTX:IDIA) Stock Catapults 38% Though Its Price And Business Still Lag The Industry
Sep 14Global Expansion And FDA Review Will Moderate Overvaluation
Key Takeaways Market optimism for rapid revenue growth may be premature, with unvalidated access, uncertain drug uptake, and regulatory outcomes adding risk to earnings expectations. Longer-term valuation appears inflated by pipeline commercialization hopes, while rising costs and increasing pricing scrutiny threaten future margins and profitability.New Forecasts: Here's What Analysts Think The Future Holds For Idorsia Ltd (VTX:IDIA)
Aug 24There's Reason For Concern Over Idorsia Ltd's (VTX:IDIA) Massive 46% Price Jump
Jul 19Improved Revenues Required Before Idorsia Ltd (VTX:IDIA) Stock's 71% Jump Looks Justified
Dec 19One Idorsia Ltd (VTX:IDIA) Analyst Has Been Cutting Their Forecasts
Nov 06Market Cool On Idorsia Ltd's (VTX:IDIA) Revenues Pushing Shares 33% Lower
Nov 04Take Care Before Jumping Onto Idorsia Ltd (VTX:IDIA) Even Though It's 25% Cheaper
Sep 18Idorsia Ltd (VTX:IDIA) Stock Rockets 26% But Many Are Still Ignoring The Company
May 30Idorsia Ltd (VTX:IDIA) Analysts Are Reducing Their Forecasts For This Year
May 26Idorsia Ltd (VTX:IDIA) Analysts Just Slashed Next Year's Revenue Estimates By 17%
May 01Industry Analysts Just Made A Captivating Upgrade To Their Idorsia Ltd (VTX:IDIA) Revenue Forecasts
Apr 05Need To Know: Analysts Are Much More Bullish On Idorsia Ltd (VTX:IDIA) Revenues
Mar 10Idorsia Ltd (VTX:IDIA) Stock Catapults 38% Though Its Price And Business Still Lag The Industry
Mar 08There's No Escaping Idorsia Ltd's (VTX:IDIA) Muted Revenues Despite A 37% Share Price Rise
Dec 28주주 수익률
| IDIA | CH Biotechs | CH 시장 | |
|---|---|---|---|
| 7D | 1.0% | 1.6% | -1.0% |
| 1Y | 167.0% | 22.6% | 6.3% |
수익률 대 산업: IDIA은 지난 1년 동안 22.6%의 수익을 기록한 Swiss Biotechs 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: IDIA은 지난 1년 동안 6.3%를 기록한 Swiss 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| IDIA volatility | |
|---|---|
| IDIA Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in CH Market | 8.4% |
| 10% least volatile stocks in CH Market | 2.3% |
안정적인 주가: IDIA의 주가는 지난 3개월 동안 Swiss 시장보다 변동성이 컸습니다.
시간에 따른 변동성: IDIA의 주간 변동성(10%)은 지난 1년 동안 안정적이었지만 Swiss 종목 중 상위 75%보다 높습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2017 | 456 | Jean-Paul Clozel | www.idorsia.com |
바이오 제약 회사인 Idorsia는 스위스, 미국, 일본, 유럽 및 캐나다에서 미충족 의료 수요에 대한 의약품을 발견, 개발 및 상업화하는 데 주력하고 있습니다. 중추신경계, 심혈관, 면역 질환, 희귀 질환 등 다양한 치료 분야에 대한 임상 개발 파이프라인을 보유하고 있습니다. 불면증 치료제인 큐비비크(성분명: 달리도렉산)를 공급하고 있습니다.
Idorsia Ltd 기초 지표 요약
| IDIA 기초 통계 | |
|---|---|
| 시가총액 | CHF 956.23m |
| 순이익 (TTM) | -CHF 111.70m |
| 매출 (TTM) | CHF 220.58m |
4.3x
주가매출비율(P/S)-8.6x
주가수익비율(P/E)IDIA는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| IDIA 손익계산서 (TTM) | |
|---|---|
| 매출 | CHF 220.58m |
| 매출원가 | CHF 123.12m |
| 총이익 | CHF 97.46m |
| 기타 비용 | CHF 209.16m |
| 순이익 | -CHF 111.70m |
최근 보고된 실적
Dec 31, 2025
다음 실적 발표일
Jul 30, 2026
| 주당순이익(EPS) | -0.44 |
| 총이익률 | 44.18% |
| 순이익률 | -50.64% |
| 부채/자본 비율 | -101.6% |
IDIA의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/04 16:24 |
| 종가 | 2026/05/04 00:00 |
| 수익 | 2025/12/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Idorsia Ltd는 10명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Rosie Turner | Barclays |
| Alistair Campbell | Berenberg |
| Sachin Jain | BofA Global Research |